# Oxular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxular

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.oxular.com
- Total disclosed funding: $51M
- Latest round: Series A (Feb 23, 2021)
- Investors on record: 9

## About

Founded in 2014 and based in the UK, Oxular Limited, formerly known as Precision Ocular is a retinal therapeutics company that develops technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Thomas Cavanagh is the co-founder and CEO of the company. In January 2024, Regeneron Pharmaceuticals, Inc. acquired Oxular Limited from MaasInvest, Consort Medical PLC, Hovione FarmaCiencia S.A., AMJ Capital, IP Group, NeoMed, Forbion, IP Group, Touchstone Innovations, N5 Capital, and V-Bio Ventures for an undisclosed amount.

The company’s potent drug products provide significant pathophysiological pathways of retinal disease. The treatment durability safely provides up to 12-months of treatment effects from a single administration. The company utilizes its technology across its pipeline to develop treatments for retinal diseases, such as diabetic macular edema and macular degeneration, as well as programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies.

## Funding rounds

- Series A, Feb 23, 2021, $30M — NeoMed, Forbion, Longview Innovation, V-Bio Ventures
- Series A, Apr 17, 2020, $3.4M — NeoMed, N5 Capital, V-Bio Ventures, AMJ Capital
- Series A, Jun 26, 2019, $4.3M — NeoMed, Consort Medical PLC, N5 Capital, V-Bio Ventures, AMJ Capital
- Series A, Jun 29, 2018, $1.3M — NeoMed, Touchstone Innovations, Consort Medical PLC, N5 Capital, V-Bio Ventures, AMJ Capital
- Series A, Jul 15, 2016, $12M — NeoMed, Touchstone Innovations, Consort Medical PLC, Hovione FarmaCiencia S.A., V-Bio Ventures

## Investors

- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A
- Consort Medical PLC — Series A
- Hovione FarmaCiencia S.A. — Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A
- N5 Capital (https://capitalatlas.ai/funds/n5-capital) — Series A
- AMJ Capital — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A